Most patients who walk into my consultation room for OCD have already done the work.

They have taken an SSRI for months — often at the high doses OCD treatment requires, which are typically higher than the doses used for depression. They have sat with a therapist trained in Exposure and Response Prevention (ERP) and pushed through exposures that felt impossible at the start. They know the loop their mind runs through, they can name the compulsions, and they have built genuine skill in resisting them.

And the OCD is still there. Not at the level it was — sometimes meaningfully less — but still loud enough that life is being organised around it. Still the first thought in the morning. Still the texture of the day.

This is the patient population for whom TMS is the next evidence-based step, and it is a population that has grown over the last few years as the FDA-approved deep TMS protocol for OCD has become more available. This article is what I tell those patients during their first consultation — what TMS for OCD is, how it differs from TMS for depression, what the protocol actually looks like, what the realistic outcomes are, and how to know whether it is the right next step.

Where TMS sits in the OCD treatment pathway

OCD has one of the best-established treatment pathways in psychiatry, and TMS does not replace the earlier steps in it — it follows them.

First-line treatment for OCD is a combination of:

  • High-dose SSRI — fluoxetine, sertraline, paroxetine, fluvoxamine, or escitalopram, usually at doses higher than those used for depression. An adequate SSRI trial for OCD is typically 10–12 weeks at the maximum tolerated dose, which is longer and higher than most patients (and many clinicians) expect.
  • Cognitive Behavioural Therapy with ERP — the gold-standard psychological treatment for OCD. ERP is not generic talk therapy. It is a structured, evidence-based protocol where patients are systematically exposed to their feared situations or thoughts while learning to resist the compulsive response.Roughly half of patients respond well to this first-line combination. The other half — and the partial responders within the first half — are where the question of what comes next becomes clinically important.

Second-line strategies include:

  • Switching to a different SSRI or to clomipramine (a tricyclic antidepressant with strong serotonergic action)
  • Augmenting the SSRI with an atypical antipsychotic in lower doses (e.g., risperidone, aripiprazole) — well-supported by evidence for a subset of patientsIntensifying 
  • ERP, often in a residential or intensive outpatient format

Third-line and neuromodulation include:

Deep TMS (dTMS) — FDA-approved for OCD since 2018, with specific protocol parameters

Standard rTMS for OCD — used in some clinical contexts with growing evidence, though not the FDA-approved indicationDeep brain stimulation (DBS) — reserved for severe, refractory OCD that has not responded to multiple prior treatments including TMS

TMS for OCD is not the same as TMS for depression. It uses a different coil, a different target, a slightly different course structure, and a unique element — symptom provocation — that does not appear in depression protocols. The next sections explain each of these.

How TMS works for OCD— the brain circuit being targeted

OCD is, in current neuroscience terms, a disorder of a specific brain circuit: the cortico-striato-thalamo-cortical (CSTC) loop. This loop connects the prefrontal cortex with the striatum, the thalamus, and back to the cortex — and in OCD, this loop becomes hyperactive in a way that produces the cardinal symptoms of intrusive thoughts and compulsive responses.

The specific cortical nodes most consistently implicated in OCD are the medial prefrontal cortex (mPFC) and the anterior cingulate cortex (ACC) — deeper and more central in the brain than the dorsolateral prefrontal cortex (DLPFC) that conventional TMS for depression targets.

Reaching these deeper targets reliably is what makes the FDA-approved OCD protocol different from depression TMS. It uses a specialised coil — the H7 coil developed for deep TMS — that produces a broader, deeper magnetic field, capable of modulating activity in mPFC and ACC without first having to penetrate through the lateral cortex.

The clinical question this protocol asks is not "can we stimulate any part of the prefrontal cortex" but "can we dampen the specific hyperactive circuit that is producing the symptoms." 

When the protocol works, the loop quiets — intrusive thoughts come less often, they carry less urgency, and the compulsive response becomes resistible in a way it was not before.

The FDA-approved protocol — what it actually looks like

The deep TMS protocol approved by the FDA for OCD has specific parameters that distinguish it from depression TMS:

Coil: H7 deep TMS coil, designed for mPFC/ACC stimulation.

Frequency: 20 Hz (higher than the 10 Hz commonly used in depression protocols).

Session length: ~18 minutes of stimulation per session.

Course length: 29 sessions over approximately 6 weeks. Most clinics deliver 5 sessions per week for the first phase, then taper the frequency in the final weeks based on response.

Symptom provocation: This is the element unique to OCD TMS. Before each stimulation session, the patient is briefly and intentionally exposed to a mild, individualised trigger of their OCD — something that activates the circuit just enough that it is "online" during the stimulation. This is not a flooding exposure and it is not ERP. It is a brief 3–5 minute activation, calibrated by the clinician, that primes the relevant neural circuit so that the stimulation that follows acts on the active network.

Provocation is one of the reasons OCD TMS requires a more clinically involved setup than depression TMS. Generic protocols don't work. The trigger has to be specific enough to activate the circuit but mild enough not to overwhelm the patient or trigger a compulsion they then have to resist alone. This is part of why we screen carefully for whether a patient can tolerate the protocol before recommending it.

What the published evidence actually shows

The pivotal multicentre trial that led to FDA approval (Carmi et al., published in the American Journal of Psychiatry in 2019) reported, at the end of six weeks of treatment:

  • Response rate (≥30% reduction in Y-BOCS score): ~38% on active dTMS vs ~11% on sham
  • Sustained response at one-month follow-up: ~45% on active dTMS vs ~18% on sham
  • Effect sizes that were clinically meaningful and statistically significant on the primary endpoint

The clinical bottom line is that around one in three to one in two patients who go through the FDA-approved deep TMS course for OCD experience a clinically meaningful reduction in symptoms — and a subset of those have sustained improvement at one-month follow-up and beyond. The numbers are not as strong as TMS response rates for depression (which sit closer to 50–60% response, see the response and remission story for depression in a separate article), but they are meaningful for a patient population that, by definition, has not responded fully to first-line treatments.

Standard rTMS for OCD — using a figure-of-eight coil rather than the H7 — has a broader and more variable evidence base. Some studies show meaningful effects targeting the supplementary motor area (SMA), bilateral DLPFC, or other regions, but these protocols are not the FDA-approved indication and are typically used in research or specialised clinical contexts.

The realistic week-by-week timeline

The general arc of a TMS course for OCD shares some structure with the realistic treatment timeline I described for depression — sleep and energy often shift before the target symptoms — but the OCD-specific signals follow their own order.

Weeks 1–2. Most patients feel minimal change in OCD symptoms during the first two weeks. The safety profile of TMS is relevant here — patients sometimes notice mild scalp discomfort or a transient headache during this period, which typically settles. Sleep often improves in week two for patients whose OCD had been disturbing sleep, which is one of the earliest non-specific signals. Some patients notice a small reduction in the "background hum" of intrusive thoughts before any change in compulsions.

Weeks 2–3. A subset of patients experience a transient worsening of OCD symptoms — similar in structure to the TMS dip sometimes seen in depression treatment. This is not failure. It can reflect the circuit being engaged and reorganised before the new equilibrium settles. As with the depression dip, it is worth flagging to your clinician but is usually not a reason to discontinue.

Weeks 3–4. For responders, this is typically when the most useful early signal arrives: the patient can begin to resist a compulsion they previously could not. Not all compulsions, not every time — but the felt urgency of the intrusive thought, and the felt cost of resisting the compulsion, both begin to drop. Patients describe it as "the thought came but I didn't have to do anything about it," or "I noticed I went a whole morning without checking."

Weeks 5–6. This is the consolidation window. Improvement that began earlier deepens. Y-BOCS scores begin to drop in measurable ways. The full clinical picture of whether the protocol is working — and at what magnitude — is usually clear by the end of week five.

The four-to-five week mark is the most useful clinical decision point. A patient who reaches session 20 with no shift in intrusive thought frequency, no change in compulsion resistibility, no sleep change, and no transient worsening that could even be a dip is statistically unlikely to convert into a strong responder in the final week of the course. That isn't failure — it is information that helps decide what comes next.

What a TMS session actually feels like for OCD

The session experience is similar in many ways to depression TMS — the patient sits in a chair, the coil is positioned and held against the scalp, and the stimulation runs for about 18 minutes — but two elements differ.

The first is the provocation phase at the start of the session. The patient and clinician have, ahead of time, identified a brief individualised trigger that activates the OCD circuit — for some patients a specific image, for others a recorded sentence, for others a brief recollection of a feared scenario. The provocation runs for a few minutes immediately before the stimulation begins. Patients sometimes find the first few sessions of provocation uncomfortable in the way ERP can be — and the discomfort almost always lessens across the course as the circuit becomes less reactive.

The second is the sensation of the stimulation itself. The H7 coil produces a broader, deeper magnetic field than a standard depression TMS coil, and patients sometimes describe the felt tapping as more diffuse and slightly more intense than the lateral scalp tapping of standard rTMS. Most patients tolerate it well after the first one or two sessions, particularly once they know what to expect.

Combining TMS for OCD with ongoing ERP

One of the questions I get most often is whether to continue ERP during the TMS course or to pause it.The general principle: continue ERP during the TMS course where possible, and ideally intensify it in the second half. The reasoning is mechanistic — TMS quiets the hyperactive circuit, and ERP teaches the patient to use the resulting capacity to resist compulsions. When the two are run together, the ERP work that previously felt impossible can become tractable in a way that locks in the gains.

This is one of the meaningful differences between TMS for OCD and TMS for depression. With depression, the patient often becomes able to engage with therapy and lifestyle change after the TMS course finishes. With OCD, the strongest outcomes tend to come when ERP is happening during the TMS course, riding the window that TMS opens.

After the course — durability and maintenance

The published data on durability after a deep TMS course for OCD shows meaningful sustained benefit at one-month follow-up in roughly 45% of responders. Longer-term data is still being generated, but the clinical pattern in our practice — and consistent with the broader TMS literature — is that responders often hold their gains for months, with a subset requiring maintenance sessions over time.

A finished TMS course for OCD is not the end of the work. The strongest outcomes are seen in patients who:Continue or intensify ERP after the course ends, while the circuit is in its more responsive stateStay on the SSRI or other medication that was supporting them, until the clinician advises a structured taperMaintain the lifestyle structures — sleep, exercise, stress management — that help keep the OCD circuit calmerRe-evaluate at the 3-, 6-, and 12-month marks with their treating clinician, and discuss maintenance sessions if early relapse signals appear

The frame I offer patients is: TMS opens a window. The work of the next year is keeping that window open.

Common questions, briefly answered

Is TMS for OCD as effective as TMS for depression? 

The numerical response rates are lower (around 38% for OCD vs 50–60% for depression), but the patient population is different — by definition, OCD patients reaching TMS have already not responded fully to SSRIs and ERP, so the comparison is not apples-to-apples.

Does TMS for OCD require stopping medications? 

Usually not. Most patients continue their SSRI through the TMS course. Medication changes during the course are minimised — we want to know what change is attributable to the TMS, not to a medication adjustment.

How is the symptom provocation handled — is it like an exposure?

 It is briefer and more controlled than an ERP exposure. The provocation is calibrated to activate the circuit without producing a full compulsive response. It is set up collaboratively with the patient ahead of time and adjusted as the course proceeds.

Can children or adolescents have TMS for OCD?

 The FDA-approved indication is for adults. Use in adolescents is being studied and is sometimes offered in specialised settings on a case-by-case basis, but it is not the standard pathway.

How does TMS compare to deep brain stimulation (DBS) for OCD?

 DBS is a surgical procedure with electrodes implanted in the brain, reserved for severe refractory cases that have not responded to multiple prior treatments including TMS. TMS is non-invasive, far lower risk, and the appropriate step before DBS would be considered.

What if TMS doesn't work for me? 

Non-response on TMS is information, not a dead end. The next steps can include extending or switching the protocol, intensifying ERP in a residential or intensive outpatient format, augmentation strategies with medication, and in severe cases consideration of DBS. We talk through the next steps at the four-to-five week clinical review.

The bottom line

TMS for OCD is the step that comes after SSRIs and ERP have been done well and have not been enough. It is FDA-approved, evidence-based, non-invasive, and works for roughly one in three patients — a meaningful share of a population that has already exhausted the first-line options. w

If you are considering TMS for OCD, the most useful next step is a structured evaluation with a psychiatrist who works with the FDA-approved deep TMS protocol. That conversation should cover whether you have completed adequate trials of first-line treatments, whether deep TMS is the right next step for your specific presentation, what realistic outcomes look like for someone with your history, how ERP will be integrated with the course, and how progress will be measured.

OCD is one of the most treatable severe psychiatric conditions when the treatment pathway is followed in order. TMS does not replace the earlier steps — but for the patients who have done the earlier steps and are still living around their OCD, it is the evidence-based next step that, until 2018, did not exist.